comparemela.com

Ernest Mceachern News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biogen, Alectos collaborate to develop Parkinson s disease treatment

Biogen has entered into a license and collaboration agreement with Alectos Therapeutics to develop and commercialise AL01811 to treat PD.

Priya singhalErnest mceachernMilling technology for pharmaceuticalsAlectos therapeuticsPackaging productsWet milling technologyChain refrigerated

Biogen Inc : Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson s Disease

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson's DiseaseAlectos to receive a $15 million upfront payment and is eligible

United kingdomWalter gilbertCharles weissmannHeinz schallerErnest mceachernAshleigh kossPriya singhalMike henckeKenneth murrayExchange commissionParkinson foundationBritish columbiaAlectos therapeuticsInterim headSir kenneth murrayNobel prize

vimarsana © 2020. All Rights Reserved.